Acute leukaemia, Acute myeloid leukaemia (AML), Blood cancers, Leukaemia
Results
Phase 3
This trial was looking at different chemotherapy plans and a type of biological therapy called gemtuzumab ozogamicin (Mylotarg) for acute myeloid leukaemia. Most of the people who took part were under the age of 60.
Please note - There is another part of this trial for people with a type of AML called acute promyelocytic leukaemia which is entered separately on our database.
Recruitment start: 15 May 2002
Recruitment end: 14 January 2009
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Alan Burnett
Experimental Cancer Medicine Centre (ECMC)
Medical Research Council (MRC)
NIHR Clinical Research Network: Cancer
Last reviewed: 22 August 2013
CRUK internal database number: 217
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
